NASDAQ: NRIXNurix Therapeutics Inc Stock
$23.21-0.37 (-1.57%)
Updated Jul 31, 2026
NRIX Price
$23.21
Fair Value Price
N/A
Market Cap
$2.41B
52 Week Low
$8.20
52 Week High
$25.08
P/E
-6.71x
P/B
5.98x
P/S
53.66x
PEG
N/A
Dividend Yield
N/A
Revenue
$36.77M
Earnings
-$341.35M
Gross Margin
100%
Operating Margin
-929.18%
Profit Margin
-928.4%
Debt to Equity
0.33
Operating Cash Flow
-$294M
Beta
1.56
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NRIX Overview
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NRIX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NRIX
Ranked#377 of 460
Ranked#377 of 460
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $252.86 | A | |
| $11.21 | A | |
| $114.49 | A |
Be the first to know about important NRIX news, forecast changes, insider trades & much more!
NRIX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NRIX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NRIX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NRIX is poor value based on its book value relative to its share price (5.98x), compared to the US Biotechnology industry average (5.23x)
P/B vs Industry Valuation
NRIX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NRIX due diligence checks available for Premium users.
Valuation
NRIX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.71x
Industry
20.12x
Market
16.06x
NRIX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.98x
Industry
5.23x
NRIX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NRIX's financial health
Profit margin
Revenue
$9.0M
Net Income
-$89.5M
Profit Margin
-990.1%
NRIX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NRIX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$535.5M
Liabilities
$132.9M
Debt to equity
0.33
NRIX's short-term assets ($456.48M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NRIX's short-term assets ($456.48M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NRIX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NRIX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$96.6M
Investing
$93.0M
Financing
$66.0k
NRIX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NRIX vs Biotech Stocks
Nurix Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.